Vintage receives warning letter
Vintage Pharmaceuticals has failed to fulfill post-marketing adverse event reporting commitments, a May 26 FDA 1warning letter states. "Our inspection revealed that your firm had never submitted an [adverse drug experience] to FDA" for any ANDA, the letter states. The company said it submitted a response to FDA and views the matter as closed...
You may also be interested in...
Serious adverse event periodic reports received by the Center for Drug Evaluation & Research increased 20% in 2004, FDA Investigator Thomas Berry said
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.